# Effectiveness and Cost-Effectiveness of a Digital Falls Prevention Program Versus Usual Care to Improve Balance, Falls Risk, and Function in Older Adults: Protocol for the Keep-On-Keep-Up Randomized Controlled Trial

**Authors:** Emma Stanmore, Amelia Parchment, Bolanle Odebiyi, Peter Bower, Chloe French, Chunhu Shi, Saima Bashir, Saima Ahmed, Dawn Dowding, Jo Dumville, Roman Kislov, Alex Thompson, Dawn A Skelton, Margaret Clarke, Chris Todd

PMC · DOI: 10.2196/78840 · JMIR Research Protocols · 2026-02-05

## TL;DR

This study tests a digital balance program for older adults to see if it improves balance, reduces falls risk, and is cost-effective compared to usual care.

## Contribution

The study introduces a digital, NHS-approved falls prevention program co-developed with older adults and therapists.

## Key findings

- The trial will assess balance function using the Berg Balance Score at 12 weeks.
- Secondary outcomes include strength, falls risk, and program usability.
- Results will determine if the program is more effective and cost-effective than standard care.

## Abstract

Falls are the primary cause of fatal and nonfatal accidental injuries in older adults. The World Falls Prevention Guidelines recommend balance-challenging, functional exercise programs as a key strategy for falls prevention, but access, uptake, and adherence to these programs in community settings remain suboptimal. Keep-On-Keep-Up (KOKU), a digital, National Health Service–approved program, was codeveloped with older adults and therapists to provide progressive, evidence-based exercises and to raise awareness of falls prevention strategies.

This trial aims to investigate the effectiveness and cost-effectiveness of the KOKU digital strength and balance program for improving balance, enhancing physical function, and reducing falls risk among community-dwelling older adults.

This is a 2-arm, parallel-group randomized controlled trial. A total of 196 community-dwelling older adults 60 years and older will be randomized to either the intervention group, comprising a digital strength and balance program (KOKU) alongside standard care (strength and balance exercise advice and a falls prevention leaflet), or to a control group, receiving standard care only. Participants receiving the intervention will be asked to exercise 3 times per week following the tailored and progressive program. Randomization will take place after recruitment and baseline data collection. The trial’s primary outcome measure is balance function (Berg Balance Score) at 12 weeks post randomization. Secondary trial outcomes include lower limb strength, health care utilization and health-related quality of life, self-reported concerns about falling, self-reported physical activity, falls risk, pain, mood, fatigue, self-reported falls, and acceptability and usability of the KOKU program. Intention-to-treat analysis and a cost-effectiveness analysis will be employed for trial data analysis. Qualitative interviews and focus groups will be undertaken with around 10 care providers and 13 participants to further understand views of the intervention and trial processes.

This study began recruitment in July 2024 and concluded in March 2025, recruiting a total of 202 participants (102 intervention group and 100 control group). Following protocol publication, data compilation and analysis will be conducted, with results anticipated to be published in 2027.

This trial will provide important evidence on whether a digital strength and balance program can improve balance and related outcomes in older adults compared with usual care.

## Full-text entities

- **Genes:** BBS2 (Bardet-Biedl syndrome 2) [NCBI Gene 583] {aka BBS, RP74}
- **Diseases:** cognitive impairment (MESH:D003072), ARC-GM (MESH:D014947), Fall (MESH:C537863), congestive cardiac failure (MESH:D006333), fragility fractures (MESH:D005600), swelling (MESH:D004487), Depression (MESH:D003866), Parkinson disease (MESH:D010300), anxiety (MESH:D001007), fracture (MESH:D050723), decline (MESH:D060825), pain (MESH:D010146), myocardial infarction (MESH:D009203), visual or hearing impairments (MESH:D006311), hypertension (MESH:D006973), auditory or visual impairment (MESH:D014786), stroke (MESH:D020521), problems (MESH:D019973), STS (MESH:D016114), fatigue (MESH:D005221)
- **Chemicals:** vitamin D (MESH:D014807), calcium (MESH:D002118), KOKU (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** KOKU — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_A9BC)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12875423/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12875423/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12875423/full.md

---
Source: https://tomesphere.com/paper/PMC12875423